151838-62-9Relevant articles and documents
Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-Activity relationships for (4-Arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives
Hayashi, Shigeo,Ohashi, Katsuyo,Mihara, Sachiko,Nakata, Eriko,Emoto, Chie,Ohta, Atsuko
, p. 345 - 364 (2016/04/19)
Nociceptin/orphanin FQ (N/OFQ) and N/OFQ peptide (NOP) receptor are expressed and distributed in various regions such as central nervous system (CNS), peripheral nervous system, immune system, and peripheral tissues. N/OFQ and NOP receptor have important
New synthesis of tic-hydantoins sigma-1 ligands and pharmacological evaluation on cocaine-induced stimulant effects
Toussaint,Debreu-Fontaine,Maurice,Melnyk
experimental part, p. 355 - 373 (2011/09/13)
Activation of the newly identified σ1 chaperone protein is involved in several aspects of the psychostimulant and addictive effects of cocaine. The development of ligands that selectively target the σ1 protein may lead to putative potent anti-cocaine agen
TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF
-
Page/Page column 26, (2010/11/28)
The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof.